(C) Novo Nordisk 2010 - Dr Mads Krogsgaard ThomsenDoing our business a little bit differently than
the others in industry

January 2010. Other business models than those based on pharmacological treatments are needed, says Dr. Mads Krogsgaard Thomsen, Executive Vice President and Chief Science Officer of Novo Nordisk. In the exclusive interview with B2Bioworld he details his company’s approach, comments stem cell applications and diabetes therapeutics in the pharmaceutical industry with some comments to competitors like Eli Lilly, Pfizer, or Sanofi-Aventis.


If you like to read this article, you can purchase it now

Please notice, when purchasing articles you agree to B2Bioworld's Terms and Conditions

Read Now - Please select your license (Prices incl. 7% VAT)
6 pages, no adverts

Article free of advertisement - 6 pages

Full Company License enquire here

Back to section

Related Editorial Articles

Sanofi: Triggering Regenerative Functions with Transplanted Cells and Small Molecules
Kurt Stoeckli, Global Head of Biological Sciences / Discovery Sanofi Aventis and Scientific Director of the research site at Vitry-Alfortville

Merck Serono on stem cell research: Clear away complete confusion of terms
Bernhard Kirschbaum, former Head of Global Research and Early Development for Merck Serono on stem cell research

Stem Cells: a discovery tool and a potential therapeutic modality
Jonathan Knowles, past Member of the Roche Executive Committee and Head of Group Research Leveraging different methods and technologies – clarifying the concept of personalised medicine

GSK: Stem Cell Research Now and in the Future
Patrick Vallance, today President Pharmaceuticals, R&D of GlaxoSmithKline on company strategy and the the role of cancer stem cells

Drug Testing with Embryonic Stem Cells
Towards standards for assays

The Myriad Way
Peter D Meldrum, at the time CEO of the genetics company on battles about patents, cancer chips, and competitors in commercial academia

Patient-centered Precision Care
Michael Christman, President of the Coriell Institute for Medical Research at Camden, New Jersey (US), talks about some tricky issues of turning research on genotyping into healthcare routines

Pfizer Regenerative Medicine (Neusentis): It really started last year…
Ruth McKernan, global CSO of Pfizer’s Regenerative Medicine Unit (today Neusentis) addresses basic and practical issues in pharmaceutical research on stem cells

Leroy Hood: Thinking Further about Stem Cells